Skip to main content

Search

Reset all filters
704 Result(s)
Sort by

empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
EC_approval_nintedanib_ILD_PF

EC_approval_nintedanib_ILD_PF

European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
CAROLINA-CARMELINA-Asia-analysis

CAROLINA-CARMELINA-Asia-analysis

CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
clinical-collaboration-with-Amgen

clinical-collaboration-with-Amgen

Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Fast-Track-Designation-NASH

Fast-Track-Designation-NASH

Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
FDA-Fast-Track-chronic-kidney-disease

FDA-Fast-Track-chronic-kidney-disease

FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
Partnering Vanderbilt WCNDD

Partnering Vanderbilt WCNDD

Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Reimagining digital healthcare worldwide

Reimagining digital healthcare worldwide

How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
View from Both Sides of the Table

View from Both Sides of the Table

Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
BTD for GlyT1 in Schizophrenia

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
collaboration-kings-college-london

collaboration-kings-college-london

Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Avian influenza prevention at the source

Avian influenza prevention at the source

Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.